| Description | The mouse antibody 12.7 has demonstrated the capability to neutralize mature human TGF-β1, TGF-β2, and TGF-β3. It exhibits a specific binding affinity to TGFB1 at 0.2 pM, and also demonstrates binding to TGF-b2 and TGF-b3 at affinities of 0.473 pM and 0.82 pM, respectively. |
| Clonality | Monoclonal |
| Host Species | Mouse |
| Target Species | Human |
| IC50 | 0.59 ng/mL (TGF-b1), 3.34 ng/mL (TGF-b2), 6.78 ng/mL (TGF-b3) |
| Affinity | KD < 0.2 pM (TGF-b1), KD = 0.473 pM (TGF-b2), KD = 0.82 pM (TGF-b3). |
| Isotype | Mouse IgG1 |
| Expression Species | HEK293F or CHO |
| Purity | >95%, determined by SDS-PAGE and SEC-HPLC |
| Endotoxin | <1 EU/mg |
| Purification | Protein G affinity purified |
| Sterility | 0.2 μM filtered |
| Formulation | PBS, pH 7.4 |
| Preservation | No preservatives |
| Stabilizer | No stabilizers |
| Storage | Store at 4°C within a week. For longer storage, aliquot and store at -20°C. |
| Application | ELISA; Neut |
| ELISA | Enzyme-Linked Immunosorbent Assay Protocol |
| WB | Western Blot Protocol |
| FC | Flow Cytometry Protocol |
| Target | TGFB |
| Alternative Name | Transforming Growth Factor Beta 1; Prepro-Transforming Growth Factor Beta-1; TGF-Beta-1; TGFB; Transforming Growth Factor, Beta 1; Transforming Growth Factor Beta-1; Camurati-Engelmann Disease; Transforming Growth Factor Beta 2; LDS4; G-TSF; TGF-beta2; ransforming growth factor beta 3; ARVD; LDS5; RNHF; ARVD1; TGF-beta3 |
| Research Area | Cancer Research |
| Related Disease | Cancer |
